For example, in patients with advanced, unresectable pancreatic cancer, wild-type KRAS status was associated with improved survival compared with mutant KRAS, as reported by Ogura et al. [13] (15.5 months vs. 8.4 months, p = 0.03). Here, KRAS is linked to familial pancreatic carcinoma.